Enliven Therapeutics (NASDAQ:ELVN) Given New $59.00 Price Target at The Goldman Sachs Group

Key Points

• The Goldman Sachs Group raised its price target on Enliven Therapeutics from $41 to $59 and maintained a buy rating, implying roughly a 46.6% upside from the prior close.
• Analyst sentiment is mixed but leans positive: five analysts rate the stock a Buy and one a Sell, giving a MarketBeat consensus of Moderate Buy with an average target of $47.80.
• Shares traded at $40.25 with a market cap of $2.45B and a negative P/E; the company beat quarterly EPS estimates (−$0.38 vs. −$0.44), but insiders have been selling (CFO sold 10,000 shares) amid high institutional ownership.

Enliven Therapeutics (NASDAQ:ELVN - Get Free Report) had its target price upped by stock analysts at The Goldman Sachs Group from $41.00 to $59.00 in a note issued to investors on Friday,Benzinga reports. The brokerage currently has a "buy" rating on the stock. The Goldman Sachs Group's price objective suggests a potential upside of 46.58% from the company's previous close.

Several other brokerages also recently weighed in on ELVN. Wall Street Zen downgraded Enliven Therapeutics from a "hold" rating to a "sell" rating in a research note on Sunday, May 3rd. Weiss Ratings reiterated a "sell (d-)" rating on shares of Enliven Therapeutics in a research note on Monday, April 20th. Mizuho increased their price target on Enliven Therapeutics from $41.00 to $45.00 and gave the company an "outperform" rating in a report on Wednesday, March 25th. Finally, HC Wainwright raised their price objective on Enliven Therapeutics from $48.00 to $56.00 and gave the company a "buy" rating in a research note on Thursday, March 26th. Five investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company's stock. According to data from MarketBeat.com, Enliven Therapeutics has an average rating of "Moderate Buy" and a consensus target price of $47.80.

Enliven Therapeutics Stock Performance

ELVN traded down $0.04 on Friday, reaching $40.25. 325,348 shares of the company's stock were exchanged, compared to its average volume of 1,184,850. Enliven Therapeutics has a twelve month low of $14.78 and a twelve month high of $48.53. The company's 50 day moving average is $37.05 and its 200-day moving average is $27.33. The company has a market cap of $2.45 billion, a price-to-earnings ratio of -21.63 and a beta of 0.32.

Enliven Therapeutics (NASDAQ:ELVN - Get Free Report) last issued its quarterly earnings data on Wednesday, May 13th. The company reported ($0.38) EPS for the quarter, topping analysts' consensus estimates of ($0.44) by $0.06. Sell-side analysts forecast that Enliven Therapeutics will post -1.7 EPS for the current year.

Insider Activity

In other news, CFO Benjamin Hohl sold 10,000 shares of the company's stock in a transaction dated Friday, March 6th. The shares were sold at an average price of $29.58, for a total value of $295,800.00. Following the sale, the chief financial officer owned 51,000 shares in the company, valued at approximately $1,508,580. This represents a 16.39% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Richard A. Heyman sold 1,230 shares of the stock in a transaction dated Tuesday, February 17th. The stock was sold at an average price of $26.18, for a total transaction of $32,201.40. Following the transaction, the director directly owned 22,647 shares in the company, valued at $592,898.46. The trade was a 5.15% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 25.90% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in ELVN. KBC Group NV acquired a new stake in shares of Enliven Therapeutics during the 1st quarter valued at approximately $38,000. Mirae Asset Global Investments Co. Ltd. increased its stake in Enliven Therapeutics by 25.9% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,884 shares of the company's stock valued at $44,000 after purchasing an additional 594 shares during the last quarter. BNP Paribas Financial Markets raised its holdings in shares of Enliven Therapeutics by 33.3% during the second quarter. BNP Paribas Financial Markets now owns 3,722 shares of the company's stock worth $75,000 after purchasing an additional 930 shares during the period. Los Angeles Capital Management LLC acquired a new stake in shares of Enliven Therapeutics during the fourth quarter worth $83,000. Finally, Quantbot Technologies LP lifted its position in shares of Enliven Therapeutics by 47.1% in the 2nd quarter. Quantbot Technologies LP now owns 4,477 shares of the company's stock worth $90,000 after buying an additional 1,434 shares during the last quarter. Institutional investors and hedge funds own 95.08% of the company's stock.

Enliven Therapeutics Company Profile

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.